60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
09 juil. 2024 06h31 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
27 juin 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
30 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.
Twin Cities Lyme Foundation and Bay Area Lyme Foundation Unite Efforts to Further Advance the Fight Against Tick-Borne Diseases
29 mai 2024 11h00 HE
|
Bay Area Lyme Foundation
PORTOLA VALLEY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced it has united efforts with Twin Cities Lyme...
New Discovery Identifies “Don’t Eat Me” Protein that Allows Lyme Bacteria to Evade Body’s Immune Response
07 mai 2024 11h01 HE
|
Bay Area Lyme Foundation
PALO ALTO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced a study finding a new mechanism of immune...
UPDATE - New Study Reveals Potential Treatment for Neurological Lyme Disease
19 avr. 2024 12h45 HE
|
Bay Area Lyme Foundation
PORTOLA VALLEY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study...
New Study Reveals Potential Treatment for Neurological Lyme Disease
18 avr. 2024 11h00 HE
|
Bay Area Lyme Foundation
PORTOLA VALLEY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study showing...
LSU Researchers' Nootkatone Studies Could Lead to Prevention of Lyme Disease
09 avr. 2024 10h00 HE
|
LSU College of Engineering
BATON ROUGE, La., April 09, 2024 (GLOBE NEWSWIRE) -- Thanks to a $550,000 National Science Foundation Partnership for Innovation grant—the largest NSF PFI grant ever awarded to LSU—LSU Chemical...
HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize by HHS and Steven & Alexandra Cohen Foundation
07 févr. 2024 11h05 HE
|
HelixBind
HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize by HHS and Steven & Alexandra Cohen Foundation
Combination Antibiotic Therapies May Be Capable of Eradicating Lyme Disease, According to Investigational Study Funded by Bay Area Lyme Foundation
21 nov. 2023 09h30 HE
|
Bay Area Lyme Foundation
PORTOLA VALLEY, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading public foundation sponsor of Lyme disease research in the US, today announced results of a laboratory...